Tue, Jul 22, 2014, 7:24 AM EDT - U.S. Markets open in 2 hrs 6 mins

Recent

% | $
Click the to save as a favorite.

IntelliPharmaCeutics International Inc. Message Board

  • threemoremonths threemoremonths Apr 19, 2014 5:58 PM Flag

    PAR has exclusive shelve space with Walgreens, CVS and Wallmart and others . . .

    They won't switch from the PAR/ IPCI's focalin to Teva or Mylan - - IPCI won't lose ground with the 15mg going of exclusitivity - we gain the 40mg dose and Teva has manufacturing issues with their version, so there will be no "flood" of other generics. $$$$$$$$$$$$$$coming in. Plus more ANDA's

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For those who are not aware of who Par is. Google them. Par is the fifth largest generic pharma in the US.

      If you go to Wiki. Under "partnership" . The *ONLY* partnership they mention IS the one with IPCI:

      "Partnerships:

      IntelliPharmaCeutics
      In 2007 Par Pharmaceutical signed a drug development collaboration with pharmaceutical research company IntelliPharmaCeutics Inc,. Under the arrangement, IntelliPharmaCeutics will apply its proprietary technology to the formulation and development of four generic drug products (ANDA's) which are bioequivalent to existing branded drugs with commercial sales in the United States. The terms of the deal provide that Par will be responsible for certain costs of development, and that IntelliPharmaCeutics will receive milestone payments, incentive payments and success-based payments along with a share of the profits of commercialization. Par will be responsible for the distribution of the drugs in the United States."

      Sentiment: Strong Buy

    • I bet IPCI beats analyst estimates for this quarter. Over $0.02.

      Sentiment: Strong Buy

 
IPCI
2.67-0.03(-1.11%)Jul 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.